Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial

202137 citationsJournal Articlehybrid Open Access

Authors

Chinadrugtrials.org CTR20160526 (12 September 2016), ClinicalTrials.gov NCT03084237 (20 March 2017), EudraCT 2016-000206-10 (27 April 2017).

Good health and well-being

Published in: BioDrugs

Volume 35, Issue 3, pp. 337-350

Field-Weighted Citation Impact: 2.68